29,452 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Entropy Technologies LP

Entropy Technologies LP acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 29,452 shares of the company’s stock, valued at approximately $1,164,000.

A number of other hedge funds and other institutional investors have also modified their holdings of IONS. Swiss National Bank grew its stake in shares of Ionis Pharmaceuticals by 4.8% during the second quarter. Swiss National Bank now owns 288,600 shares of the company’s stock worth $11,403,000 after purchasing an additional 13,300 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $378,000. Artisan Partners Limited Partnership boosted its position in shares of Ionis Pharmaceuticals by 74.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 354,962 shares of the company’s stock worth $14,025,000 after acquiring an additional 151,784 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $209,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $228,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Wells Fargo & Company increased their price target on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an “overweight” rating in a research note on Friday, August 22nd. The Goldman Sachs Group raised shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their target price for the company from $45.00 to $65.00 in a research report on Friday, September 26th. JPMorgan Chase & Co. upgraded shares of Ionis Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $49.00 to $80.00 in a research note on Wednesday, October 8th. Raymond James Financial restated a “strong-buy” rating and issued a $89.00 price objective (up previously from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. Finally, Jefferies Financial Group raised their price objective on Ionis Pharmaceuticals from $83.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.15.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $71.74, for a total transaction of $358,700.00. Following the completion of the transaction, the director owned 61,344 shares in the company, valued at approximately $4,400,818.56. This represents a 7.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian Birchler sold 8,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $76.17, for a total transaction of $609,360.00. Following the completion of the sale, the executive vice president owned 48,826 shares of the company’s stock, valued at $3,719,076.42. This trade represents a 14.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 913,362 shares of company stock valued at $59,015,008. Corporate insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Trading Up 4.1%

NASDAQ IONS opened at $76.09 on Friday. The firm’s fifty day moving average is $69.69 and its two-hundred day moving average is $51.16. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $76.78. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. The firm has a market cap of $12.32 billion, a PE ratio of -45.02 and a beta of 0.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.